Table 3.
Receiver Operating Characteristic Curve Analyses Showing the Utility of Alone or Combined Markers for Differentiating Prostate Cancer from Benign Prostate Hyperplasia
| Marker | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | AUC |
|---|---|---|---|---|---|
| MPV (fL) | 69.0 | 71.3 | 69.0 | 71.3 | 0.742 (0.677-0.800) |
| PDW (%) | 61.0 | 67.6 | 63.5 | 65.2 | 0.683 (0.615-0.746) |
| PSA (ng/ml) | 72.2 | 93.5 | 90.9 | 78.9 | 0.865 (0.810-0.908) |
| PSA+ MPV | 81.4 | 87.0 | 84.9 | 83.9 | 0.901 (0.852-0.939) |
| PSA+ PDW | 80.4 | 92.6 | 90.7 | 84.0 | 0.905 (0.856-0.941) |
| PSA+MPV+PDW | 79.4 | 93.5 | 91.7 | 83.5 | 0.935 (0.892-0.964) |
PPV, positive predictive value; NPV, negative predictive value; AUC, area under curve; PSA, prostate specific antigen; MPV, mean platelet volume; PDW, platelet distribution width.